Dear Colleagues,

Over the last several decades, treatment with anticoagulants and antiplatelet agents has shown considerable advancement but also unexpected setbacks. Current antithrombotic strategies represent the cornerstone treatment in patients with atrial fibrillation and in patients after acute coronary events. The main remaining issues are the choice of drug, dose, and duration of therapy. This is especially important in critically sick, elderly patients suffering from an array of conditions and at risk for excess bleeding. In such a scenario, there is a need for a better understanding of safe approaches to tailoring medical treatment as well as to evaluation of therapeutic targets and patients’ responses.

The special issue "Myths and Realities of Modern Antithrombotic Strategies" aims to collect high-quality original research papers and comprehensive reviews on recent evidence in relation to the antithrombotic treatment. The topics of interest include, but are not limited to:
• Acute coronary syndromes
• Myocardial infarction
• Mortality
• Anticoagulants
• Antiplatelet agents
• Pathophysiological mechanisms
• Biomarkers

Victor L. Serebruany
Guest Editor